Protecting Consumer Access to Generic Drugs Act of 2026
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Summary
The bill makes it illegal for a brand‑name drug or biologic holder to pay a generic or biosimilar filer to postpone market entry. It requires public notice, certification of such agreements, and lets the FTC impose civil penalties and injunctions. The goal is to keep medicines affordable and available sooner.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Topics
Track this bill
Get an email when HR 10887 moves: committee action, floor votes, amendments and hearings. Free, no card.
Track HR 10887 freeOr ask your AI assistant about HR 10887 directly:
Add to Claude, ChatGPT or Cursor